Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 8/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MYC | P01106 | 1/20 | 0.40 |
| ▸ | MAX | P61244 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26216793 | 1.00 | LMNA (0.49) | LMNAMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL812122 | 1.00 | LMNA (0.49) | LMNAMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL12997180 | 1.00 | LMNA (0.49) | LMNAMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL2513150 | 1.00 | LMNA (0.49) | LMNAMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL19979000 | 0.93 | LMNA (0.46) | LMNAMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL12660185 | 0.93 | LMNA (0.46) | LMNAMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL2623072 | 0.93 | LMNA (0.46) | LMNAMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL17466653 | 0.93 | LMNA (0.46) | LMNAMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL13038442 | 0.90 | LMNA (0.43) | LMNAMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL4300748 | 0.89 | LMNA (0.46) | LMNAMEN1KMT2AHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632970-B2 | Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-12-15 | — | — | US | claimed |
| US-20240257921-A1 | COMPUTATIONAL GENERATION OF CHEMICAL SYNTHESIS ROUTES AND METHODS | STANFORD RES INST INT (US) | 2024-08-01 | — | — | US | disclosed |
| US-11961595-B2 | Computational generation of chemical synthesis routes and methods | SRI INTERNATIONAL (US) | 2024-04-16 | — | — | US | disclosed |
| US-11840604-B2 | Process for preparation of block copolymer | LG CHEM, LTD. (KR) | 2023-12-12 | — | — | US | disclosed |
| US-11827745-B2 | Triblock copolymer and process for preparation thereof | LG CHEM, LTD. (KR) | 2023-11-28 | — | — | US | disclosed |
| WO-2023107419-A1 | SATURATED SPIROCYCLICS AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230123848-A1 | POLYLACTATE STEREOCOMPLEX AND PREPARATION METHOD THEREOF | LG CHEM, LTD. (KR) | 2023-04-20 | — | — | US | disclosed |
| CN-109715633-B | Dopamine-beta-hydroxylase inhibitors | 巴尔-波特拉及康邦亚股份有限公司 | 2022-03-04 | — | — | CN | disclosed |
| US-20220017523-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-ß-HYDROXYLASE INHIBITORS | BIAL - PORTELA & CA, S.A. (PT) | 2022-01-20 | — | — | US | disclosed |
| US-20210340314-A1 | TRIBLOCK COPOLYMER AND PROCESS FOR PREPARATION THEREOF | LG CHEM, LTD. (KR) | 2021-11-04 | — | — | US | disclosed |
| EP-2345634-B1 | Optically active 4-amino-3-(4-chlorophenyl) butanoic acid | SUMITOMO CHEMICAL CO (JP) | 2013-03-06 | — | — | EP | disclosed |
| EP-2345634-A1 | Optically active 4-amino-3-(4-chlorophenyl) butanoic acid | Sumitomo Chemical Company, Limited (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-20110152572-A1 | OPTICALLY ACTIVE 4-AMINO-3-(4-CHLOROPHENYL)BUTANOIC ACID | SUMITOMO CHEMICAL COMPANY, LIMITED | 2011-06-23 | — | — | US | disclosed |
| US-20110087049-A1 | METHOD OF PRODUCING PURIFIED OPTICALLY ACITVE 4-AMINO-3-(SUBSTITUTED PHENYL)BUTANOIC ACID COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED | 2011-04-14 | — | — | US | disclosed |
| EP-2298730-A1 | METHOD OF PRODUCING PURIFIED OPTICALLY ACTIVE 4-AMINO-3-(SUBSTITUTED PHENYL)BUTANOIC ACID COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2011-03-23 | — | — | EP | disclosed |
| US-7655817-B2 | Reacting an azo compound and a compound having an electron-withdrawing group attached to a monohydrogenated carbon using a nonmetal, optically active urea or thiourea catalyst to obtain the hydrazine; reducing to the amine; efficiency;stereospecific; drug product having alpha-amino structure | KYOTO UNIVERSITY (JP) | 2010-02-02 | — | — | US | disclosed |
| US-7632970-B2 | Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-12-15 | — | — | US | disclosed |
| US-20060194986-A1 | Production methods of optically active hydrazine compound and optically active amine compound | KYOTO UNIVERSITY SUMITOMO CHEMICAL COMPANY, LIMITED | 2006-08-31 | — | — | US | disclosed |
| US-20060161006-A1 | Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1640361-A2 | ASYMMETRIC UREA COMPOUND AND PROCESS FOR PRODUCING ASYMMETRIC COMPOUND BY ASYMMETRIC CONJUGATE ADDITION REACTION WITH THE SAME AS CATALYST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017523-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-ß-HYDROXYLASE INHIBITORS | DBH, SLC6A3, SLC6A2 | LMNA 2604/4885MEN1 2536/4885KMT2A 2842/4885 |
| US-20110087049-A1 | METHOD OF PRODUCING PURIFIED OPTICALLY ACITVE 4-AMINO-3-(SUBSTITUTED PHENYL)BUTANOIC ACID COMPOUND | ALAD, OR10J3, ACMSD | LMNA 3798/4885MEN1 3836/4885KMT2A 3807/4885 |
| US-20060161006-A1 | Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst | RAD18, UTP18, UBE2G2 | LMNA 4526/4885MEN1 2949/4885KMT2A 1137/4885 |
| US-20060194986-A1 | Production methods of optically active hydrazine compound and optically active amine compound | H1-0, H1-5, H1-10 | LMNA 2404/4885MEN1 3387/4885KMT2A 723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.